title: Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council.
abstract: OBJECTIVE
  To compare the efficacy of fast neutron radiotherapy versus conventional photon and/or electron radiotherapy for unresectable, malignant salivary gland tumors a randomized clinical trial comparing was sponsored by the Radiation Therapy Oncology Group in the United States and the Medical Research Council in Great Britain.
  
  
  METHODS
  Eligibility criteria included either inoperable primary or recurrent major or minor salivary gland tumors. Patients were stratified by surgical status (primary vs. recurrent), tumor size (less than or greater than 5 cm), and histology (squamous or malignant mixed versus other). After a total of 32 patients were entered onto this study, it appeared that the group receiving fast neutron radiotherapy had a significantly improved local/regional control rate and also a borderline improvement in survival and the study was stopped earlier than planned for ethical reasons. Twenty-five patients were study-eligible and analyzable.
  
  
  RESULTS
  Ten-year follow-up data for this study is presented. On an actuarial basis, there continues to be a statistically-significant p = 0.009) but there is no improvement in overall survival (15% vs. 25%, p = n.s.). Patterns of failure are analyzed and it is shown that distant metastases account for the majority of failures on the neutron arm and local/regional failures account for the majority of failures on the photon arm. Long-term, treatment-related morbidity is analyzed and while the incidence of morbidity graded "severe" was greater on the neutron arm, there was no significant difference in "life-threatening" complications. This work is placed in the context of other series of malignant salivary gland tumors treated with definitive radiotherapy.
  
  
  CONCLUSIONS
  Fast neutron radiotherapy appears to be the treatment-of-choice for patients with inoperable primary of recurrent malignant salivary gland tumors.
authors.affiliation: Department of Radiation Oncology, University of Washington Medical Center, Seattle 98195.
authors.forename: G E
authors.initials: GE
authors.lastname: Laramore
authors.forename: J M
authors.initials: JM
authors.lastname: Krall
authors.forename: T W
authors.initials: TW
authors.lastname: Griffin
authors.forename: W
authors.initials: W
authors.lastname: Duncan
authors.forename: M P
authors.initials: MP
authors.lastname: Richter
authors.forename: K R
authors.initials: KR
authors.lastname: Saroja
authors.forename: M H
authors.initials: MH
authors.lastname: Maor
authors.forename: L W
authors.initials: LW
authors.lastname: Davis
mesh_terms: D000328:Adult; D000368:Aged; D005214:Fast Neutrons / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D017785:Photons / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012468:Salivary Gland Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D013997:Time Factors